Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mindray Reports Skyrocketing Revenues Despite Global Economic Nosedive

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Mindray Medical International, China's leading medical device maker, posted a sharp rise in revenues for 2008 despite the Western world's financial meltdown, volatile currency fluctuations and a slowdown in spending at some hospitals in the U.S. and across emerging markets, according to Mindray executives

You may also be interested in...



Following Massive Loss Last Year, Chinese CRO WuXi PharmaTech Posts Remarkable Rebound During First Quarter Of 2009

BEIJING - After reporting a devastating $64 million loss for 2008, the leadership of WuXi PharmaTech said that the company had moved back into the black in the first quarter of this year with net income of more than $11 million

Following Massive Loss Last Year, Chinese CRO WuXi PharmaTech Posts Remarkable Rebound During First Quarter Of 2009

BEIJING - After reporting a devastating $64 million loss for 2008, the leadership of WuXi PharmaTech said that the company had moved back into the black in the first quarter of this year with net income of more than $11 million

China’s Mindray Forecasts Beijing’s Health Reforms – Not Obama’s – Will Boost Worldwide Revenues In 2009

BEIJING - Chinese medical device maker Mindray Medical International reported a sharp spike in earnings for 2008, and company leaders forecast that Beijing's ongoing health system reforms will strongly boost revenues this year, despite stagnating or shrinking markets in countries hit hardest by the globe-spanning economic crisis

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel